N-terminal modified exendin-4


Ontology type: sgo:Patent     


Patent Info

DATE

N/A

AUTHORS

Sung youb Jung , Chang Ki Lim , Dae Hae Song , Sung Min Bae , Young Hoon Kim , Se Chang Kwon , Gwan Sun Lee

ABSTRACT

The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3039", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "Sung youb Jung", 
        "type": "Person"
      }, 
      {
        "name": "Chang Ki Lim", 
        "type": "Person"
      }, 
      {
        "name": "Dae Hae Song", 
        "type": "Person"
      }, 
      {
        "name": "Sung Min Bae", 
        "type": "Person"
      }, 
      {
        "name": "Young Hoon Kim", 
        "type": "Person"
      }, 
      {
        "name": "Se Chang Kwon", 
        "type": "Person"
      }, 
      {
        "name": "Gwan Sun Lee", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0167-0115(99)00095-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007322357"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250050903", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013633156", 
          "https://doi.org/10.1007/s001250050903"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250050903", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013633156", 
          "https://doi.org/10.1007/s001250050903"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0167-0115(98)00155-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018910957"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0026-0495(99)90043-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052499489"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "description": "

The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases.

", "id": "sg:patent.US-9422349-B2", "keywords": [ "terminal", "invention", "N-terminal amino acid", "high activity", "pharmaceutical", "derivative", "therapeutic effect", "peptide analog", "disease" ], "name": "N-terminal modified exendin-4", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.488317.1", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-9422349-B2" ], "sdDataset": "patents", "sdDatePublished": "2019-03-07T15:36", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com.uberresearch.data.dev.patents-pipeline/full_run_10/sn-export/5eb3e5a348d7f117b22cc85fb0b02730/0000100128-0000348334/json_export_c3e5ed81.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-9422349-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-9422349-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-9422349-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-9422349-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

67 TRIPLES      14 PREDICATES      26 URIs      16 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-9422349-B2 schema:about anzsrc-for:3039
2 schema:author N11063b64517a44d1bfad87dbe6dc059b
3 schema:citation sg:pub.10.1007/s001250050903
4 https://doi.org/10.1016/s0026-0495(99)90043-4
5 https://doi.org/10.1016/s0167-0115(98)00155-4
6 https://doi.org/10.1016/s0167-0115(99)00095-6
7 schema:description <p id="p-0001" num="0000">The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases.</p>
8 schema:keywords N-terminal amino acid
9 derivative
10 disease
11 high activity
12 invention
13 peptide analog
14 pharmaceutical
15 terminal
16 therapeutic effect
17 schema:name N-terminal modified exendin-4
18 schema:recipient https://www.grid.ac/institutes/grid.488317.1
19 schema:sameAs https://app.dimensions.ai/details/patent/US-9422349-B2
20 schema:sdDatePublished 2019-03-07T15:36
21 schema:sdLicense https://scigraph.springernature.com/explorer/license/
22 schema:sdPublisher N516070d9f0ea4173930d9d8f2b5e688e
23 sgo:license sg:explorer/license/
24 sgo:sdDataset patents
25 rdf:type sgo:Patent
26 N11063b64517a44d1bfad87dbe6dc059b rdf:first N469b89c83ddc4e84965f130fa737f6ac
27 rdf:rest Nf7a66fc2e24448e6863f8450ab55926c
28 N469b89c83ddc4e84965f130fa737f6ac schema:name Sung youb Jung
29 rdf:type schema:Person
30 N516070d9f0ea4173930d9d8f2b5e688e schema:name Springer Nature - SN SciGraph project
31 rdf:type schema:Organization
32 N77d4f2da1cc44360b206686a38a18d00 rdf:first Ne7b35df934b74280a66182b7e8c82046
33 rdf:rest Ne97aa983058b476d9b160882194852d1
34 N94e018ccd1e64b289560a7ca489b73ff schema:name Dae Hae Song
35 rdf:type schema:Person
36 N9c6d33a9acb1438bb4fb0fd53c58a7ec rdf:first N94e018ccd1e64b289560a7ca489b73ff
37 rdf:rest N77d4f2da1cc44360b206686a38a18d00
38 Na596c6a24d634cccaa6b806d490f9f89 schema:name Chang Ki Lim
39 rdf:type schema:Person
40 Nab3f517b448143a08128350656d7cdef rdf:first Nc3d3a86f26af4bf698798f9a00419230
41 rdf:rest Nb90a98d5ef324ba19f95b06f013cd728
42 Nb90a98d5ef324ba19f95b06f013cd728 rdf:first Ndd3cc105e12f438fb401ff81111ce2fc
43 rdf:rest rdf:nil
44 Nc3d3a86f26af4bf698798f9a00419230 schema:name Se Chang Kwon
45 rdf:type schema:Person
46 Ndd3cc105e12f438fb401ff81111ce2fc schema:name Gwan Sun Lee
47 rdf:type schema:Person
48 Ne7b35df934b74280a66182b7e8c82046 schema:name Sung Min Bae
49 rdf:type schema:Person
50 Ne97aa983058b476d9b160882194852d1 rdf:first Nf59df79909e7424fa0d88bbe8e305648
51 rdf:rest Nab3f517b448143a08128350656d7cdef
52 Nf59df79909e7424fa0d88bbe8e305648 schema:name Young Hoon Kim
53 rdf:type schema:Person
54 Nf7a66fc2e24448e6863f8450ab55926c rdf:first Na596c6a24d634cccaa6b806d490f9f89
55 rdf:rest N9c6d33a9acb1438bb4fb0fd53c58a7ec
56 anzsrc-for:3039 schema:inDefinedTermSet anzsrc-for:
57 rdf:type schema:DefinedTerm
58 sg:pub.10.1007/s001250050903 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013633156
59 https://doi.org/10.1007/s001250050903
60 rdf:type schema:CreativeWork
61 https://doi.org/10.1016/s0026-0495(99)90043-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052499489
62 rdf:type schema:CreativeWork
63 https://doi.org/10.1016/s0167-0115(98)00155-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018910957
64 rdf:type schema:CreativeWork
65 https://doi.org/10.1016/s0167-0115(99)00095-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007322357
66 rdf:type schema:CreativeWork
67 https://www.grid.ac/institutes/grid.488317.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...